RT Journal Article
SR Electronic
T1 Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.17.20134114
DO 10.1101/2020.06.17.20134114
A1 Borghi, Maria Orietta
A1 Beltagy, Asmaa
A1 Garrafa, Emirena
A1 Curreli, Daniele
A1 Cecchini, Germana
A1 Bodio, Caterina
A1 Grossi, Claudia
A1 Blengino, Simonetta
A1 Tincani, Angela
A1 Franceschini, Franco
A1 Andreoli, Laura
A1 Lazzaroni, Maria Grazia
A1 Piantoni, Silvia
A1 Masneri, Stefania
A1 Crisafulli, Francesca
A1 Brugnoni, Duilio
A1 Muiesan, Maria Lorenza
A1 Salvetti, Massimo
A1 Parati, Gianfranco
A1 Torresani, Erminio
A1 Mahler, Michael
A1 Heilbron, Francesca
A1 Pregnolato, Francesca
A1 Pengo, Martino
A1 Tedesco, Francesco
A1 Pozzi, Nicola
A1 Meroni, Pier Luigi
YR 2020
UL http://medrxiv.org/content/early/2020/07/02/2020.06.17.20134114.abstract
AB Background Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibodies (aPL) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels of C reactive protein. The presence of anti-cardiolipin (aCL), anti-beta2-glycoprotein I (anti-β2GPI) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies was not investigated systematically. Epitope specificity of anti-β2GPI antibodies was not reported.Objective To evaluate the prevalence and the clinical association of aPL in a large cohort of COVID-19 patients, and to characterize the epitope specificity of anti-β2GPI antibodies.Methods ELISA and chemiluminescence assays were used to test 122 sera of patients suffering from severe COVID-19. Of them, 16 displayed major thrombotic events.Results Anti-β2GPI IgG/IgA/IgM were the most frequent in 15.6/6.6/9.0% of patients, while aCL IgG/IgM were detected in 5.7/6.6% by ELISA. Comparable values were found by chemiluminescence. aPS/PT IgG/IgM were detectable in 2.5 and 9.8% by ELISA. No association between thrombosis and aPL was found. Reactivity against domain 1 and 4-5 of β2GPI was limited to 3/58 (5.2%) tested sera for each domain and did not correlate with aCL/anti-β2GPI nor with thrombosis.Conclusions aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against β2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome.Competing Interest StatementM. Mahler is an employee at Inova Diagnostics, Inc. All the other authors declared no conflict of interest.Funding StatementThe study was in part supported by IRCCS Istituto Auxologico Italiano - Ricerca Corrente 2019 (PL Meroni), a grant from the Italian Ministry of Foreign Affairs and International Cooperation (MAECI) for foreign citizens and Italian citizens living abroad (A. Beltagy) and a National Institutes of Health Research Grant HL150146 (N. Pozzi).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committees in Milan (Ethic Committee Istituto Auxologico Italiano 3-04-2020) and Brescia (ASST Spedali Civili NP4187).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available at the corresponding authors